The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts

Journal of Clinical Virology

Volumn 42, Issue 4, 2008, Pages 405-408

  Sista, P ^a   Wasikowski, B ^b   Lecocq, P ^c   Pattery, T ^c   Bacheler, L ^a  

^a VircoLab Inc   (United States)

^b xLeo Inc   (United States)

^c Virco BVBA   (Belgium)

Author keywords

Atazanavir; Clinically relevant resistance; HIV 1 resistance; I50L; PI hyper susceptibility; Predicted phenotypic resistance

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR; TIPRANAVIR;

ANTIVIRAL RESISTANCE; ARTICLE; BIOINFORMATICS; DRUG SENSITIVITY; GENETIC DATABASE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; I50L GENE; MUTATOR GENE; PHENOTYPE; PRIORITY JOURNAL; VIRUS GENE; VIRUS MUTATION;

AMINO ACID SUBSTITUTION; DATABASES, NUCLEIC ACID; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION, MISSENSE; OLIGOPEPTIDES; PYRIDINES; SOFTWARE;

EID: 46149111677     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2008.03.023     Document Type: Article

References (9)

1. Colonno R., Rose R., Mclaren C., Thiry A., Parkin N., and Friborg J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naïve HIV-1-infected patients receiving ATV-containing regimens. JID 189 (2004) 1802
2. Johnson V.A., Brun-Vezinet F., Clotet B., Kuritzkes D.R., Pillay D., Shapiro J.M., et al. Update of the drug resistance mutations in HIV-1: Fall 2006. IAS-USA Top HIV Med 2006 14 (2006) 125
3. Sista P., Bacheler L., Wasikowski B., Pattery T., and McCallister S. Characterization of protease inhibitor (PI) resistance mutation I50L in routine clinical samples (RCS) between 1998 and 2005. Antiviral Ther 11 (2006) S98
4. Sista P, Wasikowski B, Pattery T, Bacheler L. The HIV-1 protease resistance mutation I50L is associated with increased susceptibility to PIs other than atazanavir. Poster H1019 presented at the 47th Annual ICAAC; 2007.
5. Van Laethem K., and Vandamme A.M. Interpreting resistance data for HIV-1 therapy management-know the limitations. AIDS Rev 8 (2006) 37
6. Vermeiren H., Van Craenenbroeck E., Alen P., Bacheler L., Picchio G., Lecocq P., et al. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Meth 145 (2007) 47
7. Weinheimer S., Discotto L., Friborg J., Yang H., and Colonno R. Atazanavir signature I50L Resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of Human Immunodeficiency Virus Type 1 genetic backbones. Antimicrob Agents Chemother 49 (2005) 3816
8. Winters BW, Montaner J, Harrigan PR, Gazzard B, Pozniak A, Miller MD, et al. Determination of clinically relevant cut-offs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data. J AIDS; in press.
9. Yanchunas J., Langley D.R., Tao L., Rose R.E., Friborg J., Colonno R.J., et al. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors. Antimicrob Agents Chemother 49 (2005) 3825